04:51 PM EDT, 06/21/2024 (MT Newswires) -- NeuroSense Therapeutics ( NRSN ) said Friday it received a notice of delisting from Nasdaq.

The staff of Nasdaq's Listing Qualifications department determined NeuroSense failed to meet the $2.5 million minimum stockholders' equity requirement and will be delisted if it does not timely request a hearing, according to the company.

The company said it plans to request a hearing to stay the delisting and will present a plan for regaining and maintaining compliance with minimum equity requirements.

Shares of the company fell 7.6% in recent trading.